Literature DB >> 25043065

Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis.

Jun Zhang1, Weici Zhang, Patrick S C Leung, Christopher L Bowlus, Sandeep Dhaliwal, Ross L Coppel, Aftab A Ansari, Guo-Xiang Yang, Jinjun Wang, Thomas P Kenny, Xiao-Song He, Ian R Mackay, M Eric Gershwin.   

Abstract

UNLABELLED: The serologic hallmark of primary biliary cirrhosis (PBC), the antimitochondrial response to the E2 component of the pyruvate dehydrogenase complex (PDC-E2), has unique features, including continuous high titers of immunoglobulin M (IgM) and IgG reactivity throughout all stages of disease, capable not only of target enzyme inhibition, but also crossreactive with chemical xenobiotics that share molecular homology with the inner lipoyl domain of PDC-E2; such chemicals have been proposed as potential etiological agents. We used flow cytometry and enzyme-linked immunospot assay (ELISPOT) to examine B-cell subsets in 59 subjects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls. Strikingly, in PBC, although there were no significant differences in B-cell phenotype subpopulations, 10% of the total IgG and IgA plasmablast population and 23% of the IgM plasmablast population were uniquely reactive with PDC-E2, detected in the CXCR7+ CCR10low plasmablast population. In contrast, plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups. Additionally, we isolated plasmablast-derived polyclonal antibodies and compared reactivity with plasma-derived antibodies and noted a distinct noncirculating tissue source of xenobiotic crossreacting antibodies. The high levels of autoantigen specific peripheral plasmablasts indicate recent activation of naive or memory B cells and a continuous and robust activation. The presence of CXCR7+ CCR10low PDC-E2-specific ASCs suggests a mechanistic basis for the migration of circulating antigen specific plasmablasts to the mucosal epithelial ligands CXCL12 and CCL28.
CONCLUSION: Our findings suggest a sustained rigorous B-cell response in PBC, likely activated and perpetuated by cognate autoantigen.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25043065      PMCID: PMC4211937          DOI: 10.1002/hep.27313

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

2.  Autoimmune acute liver failure: proposed clinical and histological criteria.

Authors:  R Todd Stravitz; Jay H Lefkowitch; Robert J Fontana; M Eric Gershwin; Patrick S C Leung; Richard K Sterling; Michael P Manns; Gary L Norman; William M Lee
Journal:  Hepatology       Date:  2011-01-05       Impact factor: 17.425

3.  Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology.

Authors:  Richard J Q McNally; Peter W James; Samantha Ducker; Oliver F W James
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

4.  Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients.

Authors:  M Eric Gershwin; Carlo Selmi; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Keith D Lindor; Marshall M Kaplan; John M Vierling
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

5.  Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect.

Authors:  F Eun-Hyung Lee; Jessica L Halliley; Edward E Walsh; Andrew P Moscatiello; Brittany L Kmush; Ann R Falsey; Troy D Randall; Denise A Kaminiski; Richard K Miller; Iñaki Sanz
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

Review 6.  Autoimmunity and environment: am I at risk?

Authors:  Daniel Smyk; Eirini I Rigopoulou; Harold Baum; Andrew K Burroughs; Diego Vergani; Dimitrios P Bogdanos
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

7.  Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus.

Authors:  Ori Wald; Orit Pappo; Rifaat Safadi; Michal Dagan-Berger; Katia Beider; Hanna Wald; Suzanna Franitza; Ido Weiss; Shani Avniel; Pal Boaz; Jacob Hanna; Gidi Zamir; Ahmed Eid; Ofer Mandelboim; Ulrich Spengler; Eithan Galun; Amnon Peled
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

8.  HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus.

Authors:  A M Jacobi; H Mei; B F Hoyer; I M Mumtaz; K Thiele; A Radbruch; G-R Burmester; F Hiepe; T Dörner
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  Fractalkine and other chemokines in primary biliary cirrhosis.

Authors:  Shinji Shimoda; Carlo Selmi; M Eric Gershwin
Journal:  Int J Hepatol       Date:  2011-08-09

10.  Analyses of CD27++ plasma cells in peripheral blood from patients with bacterial infections and patients with serum antinuclear antibodies.

Authors:  Edwin Ten Boekel; Carl E Siegert; Gert-Jan Vrielink; Veerle C Van Dam; Auke Ceelen; Wim De Kieviet
Journal:  J Clin Immunol       Date:  2007-07-18       Impact factor: 8.317

View more
  38 in total

Review 1.  IL-35 and Autoimmunity: a Comprehensive Perspective.

Authors:  Jinjung Choi; Patrick S C Leung; Christopher Bowlus; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

2.  Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics.

Authors:  Toshihiro Tanaka; Weici Zhang; Ying Sun; Zongwen Shuai; Asiya Seema Chida; Thomas P Kenny; Guo-Xiang Yang; Ignacio Sanz; Aftab Ansari; Christopher L Bowlus; Gregory C Ippolito; Ross L Coppel; Kazuichi Okazaki; Xiao-Song He; Patrick S C Leung; M Eric Gershwin
Journal:  Hepatology       Date:  2017-07-20       Impact factor: 17.425

3.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

4.  Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis.

Authors:  H Tanaka; G-X Yang; T Tomiyama; K Tsuneyama; W Zhang; P S C Leung; R L Coppel; T Joh; S G Nadler; A A Ansari; C Bowlus; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2015-06       Impact factor: 4.330

5.  Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.

Authors:  Yongyin Li; Weibin Wang; Libo Tang; Xuanqiu He; Xin Yan; Xiaoyong Zhang; Youfu Zhu; Jian Sun; Yongquan Shi; Xiong Ma; Ian R Mackay; M Eric Gershwin; Ying Han; Jinlin Hou
Journal:  Hepatology       Date:  2015-03-18       Impact factor: 17.425

Review 6.  Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.

Authors:  Amitkumar Patel; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2016-10-21

Review 7.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

8.  Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy.

Authors:  Jing-Bo Yang; Yin-Hu Wang; Wei Yang; Fang-Ting Lu; Hong-Di Ma; Zhi-Bin Zhao; Yan-Jie Jia; Wei Tang; Koichi Tsuneyama; William M Ridgway; M Eric Gershwin; Zhe-Xiong Lian
Journal:  J Autoimmun       Date:  2015-10-01       Impact factor: 7.094

9.  The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis.

Authors:  Takashi Tomiyama; Guo-Xiang Yang; Ming Zhao; Weici Zhang; Hajime Tanaka; Jing Wang; Patrick Sc Leung; Kazuichi Okazaki; Xiao-Song He; Qianjin Lu; Ross L Coppel; Christopher L Bowlus; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

Review 10.  Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.

Authors:  Guanghua Rong; Hong Wang; Christopher L Bowlus; Chunping Wang; Yinying Lu; Zhen Zeng; Jianhui Qu; Min Lou; Yan Chen; Linjing An; Yongping Yang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.